Population analysis of myelosuppression profiles using routine clinical data after the ICE (ifosfamide/carboplatin/etoposide) regimen for malignant gliomas
作者： Yoshitaka Yano , Takaaki Kodawara , Haruyuki Hongo , Ikuko Yano , Yo Kishi
DOI: 10.1002/JPS.21731
关键词:
摘要: We propose a simple and practical modeling approach for analysis of the data myelosuppression after cancer chemotherapy, which can be applied when pharmacokinetic are not available several anticancer drugs were simultaneously administered. The model equation is based on probability density function Erlang distribution. cell counts leukocytes (white blood cell, WBC), platelets (PLT), reticulocytes (RET) obtained in routine clinical laboratory tests ICE (ifosfamide/carboplatin/etoposide) regimen chemotherapy retrospectively collected from 28 patients, population was applied. time course profiles could well explained by proposed model. individual values to reach nadir Bayesian method, their medians (days) 16.8 WBC, 12.8 PLT, 8.2 RET. Such information would useful determine day visit outpatients especially additional treatment prevent side effects such as infections. applicable explain irrespective types, also because it requires only without any burden patients. © 2009 Wiley-Liss, Inc. American Pharmacists Association J Pharm Sci 98:4402–4412,
sci-hub.se 参考文章(31)
Lena E Friberg, Mats O Karlsson, Mechanistic models for myelosuppression. Investigational New Drugs. ,vol. 21, pp. 183- 194 ,(2003) , 10.1023/A:1023573429626
Jane E. Latz, James J. Rusthoven, Mats O. Karlsson, Atalanta Ghosh, Robert D. Johnson, Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Cancer Chemotherapy and Pharmacology. ,vol. 57, pp. 427- 435 ,(2006) , 10.1007/S00280-005-0035-2
Ouwerkerk J., Rodenhuis S., Schellens J., Beijnen J., Kerbusch T., Mathôt R., Keizer H., Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. European Journal of Clinical Pharmacology. ,vol. 57, pp. 467- 477 ,(2001) , 10.1007/S002280100322
Maryam Fouladi, Sylvain Baruchel, Helen Chan, R. Grant, David Malkin, Sheila Weitzman, M. L. Greenberg, Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Childs Nervous System. ,vol. 14, pp. 590- 595 ,(1998) , 10.1007/S003810050278
Jane E Latz, Mats O Karlsson, James J Rusthoven, Atalanta Ghosh, Robert D Johnson, A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Cancer Chemotherapy and Pharmacology. ,vol. 57, pp. 412- 426 ,(2006) , 10.1007/S00280-005-0077-5
L.E. Friberg, C.J. Brindley, M.O. Karlsson, A.J. Devlin, Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). European Journal of Clinical Pharmacology. ,vol. 56, pp. 567- 574 ,(2000) , 10.1007/S002280000181
Yu-Nien Sun, William J. Jusko, Transit Compartments versus Gamma Distribution Function To Model Signal Transduction Processes in Pharmacodynamics Journal of Pharmaceutical Sciences. ,vol. 87, pp. 732- 737 ,(1998) , 10.1021/JS970414Z
Mats O. Karlsson, Rüdiger E. Port, Mark J. Ratain, Lewis B. Sheiner, A population model for the leukopenic effect of etoposide. Clinical Pharmacology & Therapeutics. ,vol. 57, pp. 325- 334 ,(1995) , 10.1016/0009-9236(95)90158-2
Lewis B. Sheiner, Stuart L. Beal, Some suggestions for measuring predictive performance Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 9, pp. 503- 512 ,(1981) , 10.1007/BF01060893
Radojka M. Savic, Daniël M. Jonker, Thomas Kerbusch, Mats O. Karlsson, Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 34, pp. 711- 726 ,(2007) , 10.1007/S10928-007-9066-0